Valbiotis SA
0.55
EUR
+0.02
(+3.36%)
ISIN
FR0013254851
Return %
Stock
S&P 500
1Y
-24.32
14.20
3Y
-90.00
81.12
5Y
-92.00
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Sebastien M. Peltier
- Full Time Employees
- 50
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- rue Paul Vatine Perigny IF France 17180
- IPO Date
- Jun 7, 2017
- Website
- valbiotis.com
- Similar Companies
- Business
- Valbiotis S.A. is a France-based biotechnology company specializing in the research, development, and marketing of scientifically validated dietary supplements aimed at preventing and managing metabolic and cardiovascular diseases. The company's main products include its proprietary range of plant-based dietary supplements such as Valbiotis®PRO Cholesterol and the newly launched Valbiotis®PRO Metabolic Health, both targeting the prevention of metabolic disorders including type 2 diabetes, obesity, and altered metabolic syndrome parameters. These products are based on patented active substances like TOTUM- 63, which have undergone extensive clinical testing and are designed to provide natural, non-drug, multi-targeted preventive solutions. Valbiotis also has in development other supplements targeting blood pressure (TOTUM- 854) and hepatic steatosis (TOTUM- 448), expanding its portfolio in metabolic health nutrition. Founded in 2014 and headquartered in La Rochelle, France, Valbiotis operates primarily in France with licensing agreements for international markets and collaborates extensively with academic research centers. The company leverages a multi-target prevention strategy using plant-based substances validated through rigorous scientific and clinical studies. Recent major developments include the commercial launch of Valbiotis®PRO Cholesterol in May 2024 and the scheduled launch of Valbiotis®PRO Metabolic Health in early 2025, supported by a commercial strategy involving direct pharmacy distribution and e-commerce. Valbiotis has also established strategic industrial partnerships and maintained robust inventory preparation for scaling production and market penetration. The company received significant financial backing from the European Union, including the European Regional Development Fund, and continues to focus on innovation in metabolic disease prevention through natural nutritional solutions. Valbiotis markets its products in France and develops licensing partnerships internationally. Its target markets include individuals at risk of metabolic and cardiovascular diseases, healthcare professionals, and pharmacies. The company builds its presence with a dedicated in-house sales force and has been recognized for its innovation in preventive healthcare. The strategic focus on natural dietary supplements for disease risk reduction positions Valbiotis as an innovator in the biotechnology and pharmaceutical sectors addressing public health challenges related to metabolic health.